Resverlogix Corp T.RVX

Alternate Symbol(s): RVXCF

Healthcare Biotechnology

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.

TSX:RVX - Post by User

Resverlogix Corp > Q&A with Sarah Re, May 9 2022 News Release

<< Previous

Bullboard Posts

Next >>

Comment by G1945Von Jun 02, 2022 11:18am

345 Views

Post# 34726565

RE:Q&A with Sarah Re, May 9 2022 News Release

G1945V wrote: May 27, 2022:

GV: Hello Sarah. This is about the news release of May 9, 2022, regarding the Type C meeting to review the Phase 3 study of apabetalone in high-risk Covid 19 patients.

I am focusing on a specific part of the news release which states the following.

" Resverlogix will conclude its Phase 2 trial in hospitalized COVID-19 patients early, thus focusing its resources on the advanced Phase 3 program."

What exactly is meant by concluding Phase 2, has it been abandoned, If so for what reason, after so much that was spoken by our CEO Donald McCaffrey from time to time since the program was launched on March 23, 2020, and the millions of dollars spent in relation to Aversana's involvement. To go from this to that so to speak does not explain what is going on and leaves shareholders with complete comprehension. We deserve an honest-to-goodness explanation.

I trust you will provide the best possible explanation of what is meant by, "Resverlogix will conclude its Phase 2 trial in hospitalized COVID-19 patients early, ..." and the reasons behind it. Thank you.

June 1, 2022

(*) Sarah: Hi, GV, RVX in partnership with EVERSANA as announced will conclude the phase 2 trial in hospitalized patients early and to refocus resources on the phase 3 trial where apabetalone has the greatest potential to impact patient outcomes in high-risk COVID-19 outpatients. CORAL will assess safety and efficacy of apabetalone in preventing serious health outcomes in high-risk COVID-19 patients.

Please review newly released data on COVID-19 and the high-risk CVD patient population. Please refer to the following articles: https://jamanetwork.com/journals/jama/fullarticle/2789793 and https://www.nature.com/articles/s41591-022-01689-3

GV: Thank you for that Sarah, however, you have not explained what is meant by, "Resverlogix will conclude its Phase 2 trial in hospitalized COVID-19 patients early, ..." and the reasons behind it. Will Phase 2 be completed as planned, or will it be abandoned, and was anything gained by it that would benefit the Phase 3 trial, or was it a total waste of time and money? Please explain.

Sarah: GV, the study has not been abandoned – but concluded early without completion as originally planned. It is my understanding that any data from this study will be potentially presented at a scientific forum. Reasoning as explained.... (*)

G1945V

June 2, 2022:

GV: Thank you again, Sarah.

Are you at liberty to tell me how many were recruited for the Covid 19 Open-label Study before it was terminated?

Sarah:
I do not have that information however it would come out in a data release.

G1945V